In this podcast, Brian Wojciechowski, MD, Breastcancer.org medical adviser, discusses some of the research that was published in July 2014.
In this podcast, Brian Wojciechowski, M.D., Breastcancer.org medical adviser, discusses some of the research that was published in July 2014. Listen to the podcast to hear Dr. Wojciechowski talk about:
Running time: 20:50
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
April 19th 2024Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.